Invention Grant
- Patent Title: Acellular pro-tolerogenic compositions for treatment/prevention of graft rejection
-
Application No.: US14414415Application Date: 2013-07-12
-
Publication No.: US10039788B2Publication Date: 2018-08-07
- Inventor: Mark D. Scott , Duncheng Wang , Wendy M. Toyofuku
- Applicant: CANADIAN BLOOD SERVICES
- Applicant Address: CA Ottawa
- Assignee: CANADIAN BLOOD SERVICES
- Current Assignee: CANADIAN BLOOD SERVICES
- Current Assignee Address: CA Ottawa
- Agency: Norton Rose Fulbright US LLP
- Priority: CA2782942 20120712
- International Application: PCT/CA2013/050545 WO 20130712
- International Announcement: WO2014/008610 WO 20140116
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/11 ; A61K35/17 ; C12N5/0783 ; A61K39/00 ; C12N15/113 ; A61K9/00 ; A61K35/14 ; A61K47/48 ; A61K35/00 ; A61K35/12

Abstract:
This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory T cells (Treg) and/or decreasing the level of pro-inflammatory T cells (Th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of miRNAs and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer. Therapeutic uses for preventing or limiting graft rejection and GVHD of such compositions are also provided.
Public/Granted literature
- US20150196597A1 Acellular Pro-Tolerogenic Compositions for Treatment/Prevention of Graft Rejection Public/Granted day:2015-07-16
Information query